Increased Expression of DDX39 in Uveal Melanoma Is Associated With Patient Prognosis.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-04-01 DOI:10.21873/anticanres.17547

Shin-Nosuke Yamashita, Yoshiatsu Tanaka, Shajedul Islam, Takao Kitagawa, Kazuhiro Tokuda, Durga Paudel, Sarita Giri, Tohru Ohta, Fumiya Harada, Hiroki Nagayasu, Yasuhiro Kuramitsu

{"title":"Increased Expression of DDX39 in Uveal Melanoma Is Associated With Patient Prognosis.","authors":"Shin-Nosuke Yamashita, Yoshiatsu Tanaka, Shajedul Islam, Takao Kitagawa, Kazuhiro Tokuda, Durga Paudel, Sarita Giri, Tohru Ohta, Fumiya Harada, Hiroki Nagayasu, Yasuhiro Kuramitsu","doi":"10.21873/anticanres.17547","DOIUrl":null,"url":null,"abstract":"Background/aim: Uveal melanoma is one of the most common primary intraocular tumors. It arises from melanocytes in the uvea and accounts for 3-5% of all melanomas. Uveal melanoma has a high metastatic potential. About half of the patients develop distant metastases including the liver, and the median survival time has been reported to be 4-5 months. Although the primary treatment for uveal melanoma has evolved from enucleation to eye-saving local treatment, there is no impact on the occurrence of distant metastases or overall survival. At least 50% of patients will develop metastases and the 3-year survival rate drops rapidly to 13%. Therefore, it is important to find prognostic biomarkers and therapeutic molecular targets that improve survival in patients with uveal melanoma. DDX39 is an Asp-Glu-Ala-Asp (DEAD) box RNA helicase required for mRNA transcription, splicing, and transport. There have been several reports of DDX39 over-expression in tumor tissues and cells, and we reported that patients with adrenocortical carcinoma with high DDX39 expression had a significantly worse prognosis. The clinicopathological involvement of DDX39 in uveal melanoma has not yet been documented.Materials and methods: We analyzed DDX39 mRNA expression and survival in patients with uveal melanoma using the GEPIA2 and UALCAN platforms.Results: DDX39 was found to be up-regulated in uveal melanoma tissues with increasing stage, and this up-regulated expression was inversely correlated with prolonged patient survival.Conclusion: DDX39 may be one of the potential prognostic biomarkers for patients with uveal melanoma.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1661-1666"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17547","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Uveal melanoma is one of the most common primary intraocular tumors. It arises from melanocytes in the uvea and accounts for 3-5% of all melanomas. Uveal melanoma has a high metastatic potential. About half of the patients develop distant metastases including the liver, and the median survival time has been reported to be 4-5 months. Although the primary treatment for uveal melanoma has evolved from enucleation to eye-saving local treatment, there is no impact on the occurrence of distant metastases or overall survival. At least 50% of patients will develop metastases and the 3-year survival rate drops rapidly to 13%. Therefore, it is important to find prognostic biomarkers and therapeutic molecular targets that improve survival in patients with uveal melanoma. DDX39 is an Asp-Glu-Ala-Asp (DEAD) box RNA helicase required for mRNA transcription, splicing, and transport. There have been several reports of DDX39 over-expression in tumor tissues and cells, and we reported that patients with adrenocortical carcinoma with high DDX39 expression had a significantly worse prognosis. The clinicopathological involvement of DDX39 in uveal melanoma has not yet been documented.

Materials and methods: We analyzed DDX39 mRNA expression and survival in patients with uveal melanoma using the GEPIA2 and UALCAN platforms.

Results: DDX39 was found to be up-regulated in uveal melanoma tissues with increasing stage, and this up-regulated expression was inversely correlated with prolonged patient survival.

Conclusion: DDX39 may be one of the potential prognostic biomarkers for patients with uveal melanoma.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.